DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid)
supplementation slows the progression of cognitive and functional decline in mild to moderate
Alzheimer's disease (AD).
Phase:
Phase 3
Details
Lead Sponsor:
Alzheimer's Disease Cooperative Study (ADCS)
Collaborators:
DSM Nutritional Products, Inc. National Institute on Aging (NIA)